📊

Executive Summary

NDA/MAA-accepted once-weekly TransCon CNP (navepegritide) for achondroplasia in children, the only treatment showing benefits beyond height vs placebo in a pivotal trial

TransCon_CNP_navepegritide

· TransCon prodrug

NDA Submitted

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy